西地那非联合安立生坦对慢性肺心病急性期疗效及心肺功能的影响

Effects of sidinafi combined with ampsishengtan on acute curative effect and cardiopulmonary function of chronic pulmonary heart disease

目的探讨西地那非联合安立生坦对慢性肺心病急性期患者的治疗效果,并分析该疗法对患者心肺功能的影响.方法抽取北大医疗海洋石油医院普内科2022年2月-2023年12月收治的慢性肺心病急性期患者80例为研究对象,采用随机数字表法将患者分为对照组和试验组各40例,对照组行安立生坦治疗,试验组行西地那非+安立生坦治疗,治疗2周后,观察两组心功能指标[右室射血分数(RVEF)、心搏量指数(SVI)、心脏指数(CI)、肺动脉平均压(MPAP)]、肺功能指标[用力肺活量(FVC)、肺总量(TLC)、最大呼气中期流速(MMFR)、第一秒用力呼气容积(FEV1)与用力肺活量(FVC)比值(FEV1/FVC)]变化情况,并评估两组疗效及用药安全性.结果①关于治疗后心功能指标水平,试验组显著优于对照组,差异有统计学意义(P<0.05);②关于治疗后肺功能指标水平,试验组显著高于对照组,差异有统计学意义(P<0.05);③关于治疗总有效率,试验组显著高于对照组,差异有统计学意义(P<0.05);④关于不良反应发生率,试验组与对照组比较,差异无统计学意义(P>0.05).结论针对慢性肺心病急性期患者,予以西地那非联合安立生坦治疗,可修复患者心肺功能,缓解患者不适症状,改善患者病情,且联合用药不良反应轻微,安全性高,值得推广.

Objective To explore the therapeutic effect of sildenafil and allisentan on patients with acute chronic pulmonary heart disease,and to analyze the effect of the therapy on the cardiopulmonary function of patients.Methods 80 patients with acute chronic pulmonary heart disease admitted to the Department of General Internal Medicine of Peking University Medical Offshore Petroleum Hospital from February 2022 to December 2023 were taken as the study subjects.The patients were divided into 40 cases in the control group and 40 cases in the experimental group.The control group was treated with Anlishengtan,and the experimental group was treated with Xidinafel+Anlishengtan treatment,after two weeks of treatment,observe two groups of cardiac function indicators[left ventricular ejection fraction(LVEF),heart rate index(SVI),heart index(CI),pulmonary artery average pressure(MPAP)],lung function index[force lung capacity(FVC),total lung volume(TLC),maximum The changes of mid-term exhalation flow rate(MMFR),the ratio of first-second exhalation volume(FEV1)and force lung capacity(FVC)(FEV1/FVC),and the efficacy and drug safety of the two groups were evaluated.Results①Regarding the level of cardiac function index after treatment,the experimental group was significantly better than that of the control group,and the difference was statistically significant(P<0.05);②Regarding the level of lung function index after treatment,the experimental group was significantly higher than that of the control group,and the difference was statistically significant(P<0.05);③About the total efficiency of treatment,the experimental group significantly higher than the control group,the difference is statistically significant(P<0.05);④Regarding the incidence of adverse reactions,compared with the control group,the difference has no statistical significance(P>0.05).Conclusion For patients with acute chronic pulmonary heart disease,sildinafel combined with Anlishengtan treatment can repair the patient's cardiopulmonary function,relieve the patient's uncomfortable symptoms,improve the patient's condition,and the adverse reaction of combined drug use is mild,safe,and is worth promoting.